Table 1 Baseline characteristics of participants
Variables | All subjects (n = 136) | Risperidone (n = 69) | Placebo (n = 67) | P valuea | |
|---|---|---|---|---|---|
Age (yr) | 7.6 ± 2.8 | 7.2 ± 2.4 | 8.0 ± 3.1 | 0.10 | |
Sex (girl) | 47(34.6) | 17(36.2) | 30(63.8) | 0.02 | |
Weight (kg) | 26.9 ± 14.4 | 27.5 ± 16.0 | 26.1 ± 12.4 | 0.66 | |
Height (cm) | 121.1 ± 17.1 | 121.3 ± 16.8 | 120.7 ± 17.8 | 0.88 | |
BMI Z-score | -0.11 ± 1.31 | 0.16 ± 1.30 | -0.26 ± 1.31 | 0.19 | |
BMI (kg/m2) | 16.3 ± 2.9 | 16.1 ± 2.5 | 16.1 ± 2.5 | 0.56 | |
psychiatric disorders | 69(50.7) | 34(49.3) | 35(50.7) | 0.43 | |
SES b | |||||
strong | 66 (48.5) | 32(46.3) | 34(50.7) | 0.78 | |
weak or moderate | 70(51.4) | 37(53.6) | 33(49.2) | 0.65 | |